Drug Database
Back to search

Poland· PL-100304151

Stoperan S

A loperamide product containing loperamidi hydrochloridum + simeticonum, registered in Poland by US Pharmacia Sp. z o.o.. The same ATC class is registered in 18 of our 19 countries.

ATC A07DA03

Checked against URPL (Poland) on

Informational only — not a medical device.

SOURCE REGISTER · PLURPL (Poland)normalisedStoperan SATCA07DA03REGISTER NO.PL-100304151PACKS LISTED10CHECKEDSeptember 27, 2026
Compare price across countriesPer daily dose · free accountAsk the assistant about loperamidi hydrochloridum + simeticonumAnswers with sources · free accountCheck interactionsSeverity free · mechanism on Growth

Where it is registered

Loperamide is registered in 18 of 19 countries.

Countries holding a registration under ATC A07DA03 (loperamide), each read from that country’s own register.

  • This record: Poland, from URPL (Poland)
  • 10 of them publish a price we can compare per daily dose
Search loperamide products by name

Loperamide · ATC A07DA03

18 / 19 countries

  • Belgiumprice
  • Canada
  • Czechiaprice
  • Denmark
  • Finlandprice
  • Franceprice
  • Germany
  • Icelandprice
  • Ireland
  • Japan
  • Netherlands
  • Norwayprice
  • Polandprice
  • Spainprice
  • Sweden
  • Switzerlandprice
  • United Kingdom
  • United Statesprice
Blue: a registration under this ATC code. The ringed marker is this record’s country. Markets marked price publish a price we can compare per daily dose.

Price per daily dose

What a daily dose of loperamide costs, country by country.

Normalised to the WHO defined daily dose (10 mg), the median price runs from $0.55 in France to $2.29 in Switzerland — a ×4.2 gap.

  • 2 markets with a comparable price for this class
  • Public list prices, converted to USD at the rate date shown
Open the full comparison — free accountDrug prices for market access

Loperamide · price per daily dose (10 mg)

USD · FX 28 Sept 2026

  • CH Switzerland$2.29
  • FR France$0.55
Median listed price per WHO defined daily dose, in each market that publishes a price. Open the full comparison

The record

At a glance

URPL (Poland)
Active substance
Loperamidi hydrochloridum + Simeticonum
Manufacturer
US Pharmacia Sp. z o.o.
Country
Poland (PL)
ATC code
A07DA03
ATC class
Loperamide
Defined daily dose
10 mg, O
Reimbursed
Not published by this register
Source register
URPL (Poland)
Last checked
September 27, 2026

Packs & prices · 10

  • gtin
    05909991087456
  • gtin
    05909991087463
  • gtin
    05909991087470
  • gtin
    05909991087487
  • gtin
    05909991087494
  • gtin
    05909991087500
  • gtin
    05909991087524
  • gtin
    05909991087531
  • gtin
    05909991087548
  • gtin
    05903031289732

Regulatory notes

No shortage, Orange Book or US label notes for this record.

Interactions

723 interactions on record for loperamide.

Graded by severity as the source publishes them — 48 severe. Severity grades are free for everyone; mechanism and management come with Growth.

  • Severity for every pair — free, no plan needed
  • The source, licence and sync date on every record
  • Mechanism and what to do for each pair — Growth plan
Check loperamide against other medicinesHow interaction checks work

Loperamide · interactions on record

723 records

  • 48 severe
  • 337 moderate
  • 1 minor
  • 337 info

Most severe, free to view

  • CimetidineA02BA01severe
  • RanitidineA02BA02severe
  • PapaverineA03AD01severe
  • LonafarnibA16AX20severe
  • Interaction severity from DDInter 2.0 (Xiong G. et al., Nucleic Acids Res.), licensed CC BY-NC 4.0 — free for non-commercial use only; not covered by the Drug Database commercial licence.
Mechanism and what to do, in the interaction check
Source: DDInter 2.0 · synced 29 Sept 2026. Grades as the source publishes them.

Same class

Other records under A07DA03

Loperamide, as other registers publish it.

All loperamide products

Sourced from a public register and reproduced with attribution. Drug Database is not affiliated with, endorsed by, or a partner of URPL (Poland). This is an informational data service and not a medical device — verify against the official source of record before any clinical decision.

For developers

The same record over the API, and the raw payload
GET /v1/drugs/fe3ac8a5-f4f5-4d8a-9abc-c75d60c7d56c
GET /v1/drugs/fe3ac8a5-f4f5-4d8a-9abc-c75d60c7d56c?format=fhir

Every response carries last_synced_at, so freshness is a field rather than a promise. Below is exactly what the ingestion wrote, before any presentation — the same JSON the API returns under payload.

{
  "form": "Tabletki",
  "source": "urpl",
  "strength": "2 mg + 125 mg",
  "packaging": "05909991087456 ¦ OTC ¦ 86722\n6 tabl.\n05909991087463 ¦ OTC ¦ 86723\n8 tabl.\n05909991087470 ¦ OTC ¦ 86724\n10 tabl.\n05909991087487 ¦ OTC ¦ 86725\n12 tabl.\n05909991087494 ¦ OTC ¦ 86726\n15 tabl.\n05909991087500 ¦ OTC ¦ 86727\n16 tabl.\n05909991087524 ¦ OTC ¦ 86728\n18 tabl.\n05909991087531 ¦ OTC ¦ 86729\n20 tabl.\n05909991087548 ¦ OTC ¦ 86730\n30 tabl.\n05903031289732 ¦ OTC ¦ 141742\n24 tabl.",
  "substance": "Loperamidi hydrochloridum 2 mg + Simeticonum 125 mg",
  "common_name": "Loperamidi hydrochloridum + Simeticonum",
  "pl_product_id": "100304151",
  "pozwolenie_nr": "21502",
  "auth_procedure": "DCP",
  "authorisation_validity": "Bezterminowe"
}
API referenceMCP serverPlans

See everything about loperamide.

This page is the registration. A free account adds the label text as the regulator wrote it, what it costs per daily dose across the markets that publish a price, a feed of what changes in the registers, and an assistant that answers with its sources. Interaction severity is free; mechanism and management are on the Growth plan. No card, nothing to install.

Try it freeOpen in the console